ExpreS2ion announces 6.7 MSEK EU Horizon 2020 grant for the development of a unique influenza vaccine
Hørsholm, Denmark, March 31, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the international next-generation influenza vaccine consortium INDIGO, led by the University of Amsterdam with ExpreS2ion as a participating member, has been awarded a 10.0 MEUR Horizon 2020 grant from the EU. ExpreS2ion’s participation is directly awarded 0.6 MEUR (approx. 6.7 MSEK) of this grant, which is estimated to be recognised as revenue evenly from H2 2020 through H2 2021.The grant will support the development of a next-